Venker Eric
President & Immunovant CEO
Venker Eric has filed 24 SEC Form 4 filings (73 transaction rows) across 2 companies, including ROIV, IMVT, with disclosures dating back to 2025. 20 of those filings fall inside the rolling window. Most recent filing: Oct 22, 2026.
On the most recent filing, Venker Eric is listed as President & Immunovant CEO at Roivant Sciences Ltd. Inside the rolling window, Venker Eric reported no open-market purchases and 17 open-market sales totaling $77.4M in ROIV and IMVT. The largest disclosed transaction in the window is a sale of 200,000 ROIV shares on Sep 30, 2026, worth $7.3M.
Companies traded
Other insiders at ROIV
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$77.4M
reported sales (SEC code S)
Companies
2
in the rolling window
| Source | |||||||
|---|---|---|---|---|---|---|---|
| ROIV | President & Immunovant CEO | Sale | 200,000 | $7.0M | Oct 22 | SEC ↗ | |
| IMVT | Chief Executive Officer | Sale | 3,506 | $120K | Oct 5 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $7.3M | Oct 2 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $7.2M | Sep 2 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $7.0M | Jul 30 | SEC ↗ | |
| IMVT | Chief Executive Officer | Sale | 3,092 | $119K | Jul 6 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $6.6M | Jun 26 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $6.1M | May 22 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $5.9M | Apr 22 | SEC ↗ | |
| IMVT | Chief Executive Officer | Sale | 14,229 | $343K | Apr 3 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $5.6M | Mar 19 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $5.3M | Feb 18 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $4.4M | Jan 14 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $4.5M | Dec 29 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 75,000 | $1.7M | Dec 29 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $4.2M | Dec 11 | SEC ↗ | |
| ROIV | President & Immunovant CEO | Sale | 200,000 | $4.0M | Nov 7 | SEC ↗ |
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Oct 17, 2025 | ROIV | Sale | $2.0M |
| Oct 16, 2025 | ROIV | Sale | $5.4M |
| Oct 15, 2025 | ROIV | Sale | $7.0M |
| Oct 13, 2025 | ROIV | Sale | $337K |
| Oct 9, 2025 | ROIV | Sale | $1.7M |
| Oct 8, 2025 | ROIV | Sale | $2.2M |
| Oct 7, 2025 | ROIV | Sale | $5.7M |
| Oct 6, 2025 | ROIV | Sale | $2.8M |
| Sep 23, 2025 | ROIV | Sale | $9.1M |
| Sep 22, 2025 | ROIV | Sale | $1.5M |
| Sep 22, 2025 | ROIV | Sale | $4.7M |
| Sep 19, 2025 | ROIV | Sale | $10.2M |
Frequently asked questions
How many SEC Form 4 filings has Venker Eric made?
Venker Eric has filed 24 SEC Form 4 filings (73 transaction rows) across 2 companies, including ROIV, IMVT since 2025.
Which companies does Venker Eric trade?
Venker Eric has filed SEC Form 4 disclosures for 2 companies, including ROIV, IMVT.
When was Venker Eric's most recent SEC Form 4 filing?
Venker Eric's most recent SEC Form 4 filing on Tracefour is dated Oct 22, 2026.
What is Venker Eric's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Venker Eric is listed as President & Immunovant CEO.
What is Venker Eric's total buy and sell value in the current window?
Inside the rolling retention window, Venker Eric bought $0 and sold $77.4M based on SEC Form 4 filings.
What was Venker Eric's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 200,000 ROIV shares on 2026-09-30, worth $7.3M, per SEC Form 4 filings.